Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alzamend Neuro (DE:9ZT0)
FRANKFURT:9ZT0
Alzamend Neuro (9ZT0) Stock Price & Analysis
0 Followers
9ZT0 Stock Chart & Stats
Day’s Range€2.16 - €2.16
52-Week Range― - ―
Previous Close€2.16
Volume0.00
Average Volume (3M)N/A
Market Cap
$9.45M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Mar 16, 2023EPS Estimate
-€0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.53Price Target Upside63.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Alzamend Neuro News
9ZT0 FAQ
What was Alzamend Neuro’s price range in the past 12 months?
Currently, no data Available
What is Alzamend Neuro’s market cap?
Currently, no data Available
When is Alzamend Neuro’s upcoming earnings report date?
Alzamend Neuro’s upcoming earnings report date is Mar 16, 2023 which is 407 days ago.
How were Alzamend Neuro’s earnings last quarter?
Alzamend Neuro released its earnings results on Mar 15, 2022. The company reported -€0.424 earnings per share for the quarter, the consensus estimate of -€0.424 by €0.
Is Alzamend Neuro overvalued?
According to Wall Street analysts Alzamend Neuro’s price is currently Undervalued.
Does Alzamend Neuro pay dividends?
Alzamend Neuro does not currently pay dividends.
What is Alzamend Neuro’s EPS estimate?
Alzamend Neuro’s EPS estimate is -€0.56.
How many shares outstanding does Alzamend Neuro have?
Currently, no data Available
What happened to Alzamend Neuro’s price movement after its last earnings report?
Alzamend Neuro reported an EPS of -€0.424 in its last earnings report, expectations of -€0.424. Following the earnings report the stock price went down -3.224%.
Which hedge fund is a major shareholder of Alzamend Neuro?
Currently, no hedge funds are holding shares in DE:9ZT0
---
Alzamend Neuro Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€3.53 (63.52% Upside)
€3.53 (63.52% Upside)
Blogger Sentiment
Bullish
DE:9ZT0 Sentiment 100%
Sector Average 68%
Sector Average 68%
Insider Transactions
Bought Shares
Worth $10.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.00%
12-Months-Change
Fundamentals
Return on Equity
-277.69%
Trailing 12-Months
Asset Growth
-78.48%
Trailing 12-Months
Company Description
Alzamend Neuro
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline of product candidates consist of two novel therapeutic drug candidates namely AL001 a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, and; AL002 a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient's immunological system to combat Alzheimer's.
---
9ZT0 Stock 12 Months Forecast
Average Price Target
€3.53
▲(63.52% Upside)
Technical Analysis
Alzamend Neuro
―
Annovis Bio
―
Anavex Life Sciences
―
Avrobio
―
Bioxcel Therapeutics
―
Best Analysts Covering 9ZT0
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-57.10%
reiterated a buy rating 7 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -57.10% per trade.
---